Therefore, inhibiting the circFGFR1/CXCR4 pathways in NSCLC cells may provide a novel opportunity to inhibit resistance to anti-PD-1 immunotherapy in the treatment of NCSLC. This evidence concerns the gene CXCR4 and non-small cell lung carcinoma.